
The meta-analysis evaluated the impact of age on immune checkpoint inhibitors (ICI) efficacy in advanced non-small cell lung cancer (NSCLC). Despite analyzing 13 clinical trials, no significant differences were found in overall survival (OS) between patients aged 75 and older versus younger patients. The study suggests that immunotherapy remains equally effective across different age groups in treating advanced NSCLC.
Like
Save
Share